7:30 AM ET
8-K
Business Update
Palvella Therapeutics Business Update
Palvella Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted it Priority Review. The application seeks approval for the treatment of microcystic lymphatic malformations, with a PDUFA target action date set for February 28, 2027.